[detailed] How does BAT layout mobile medical care?

In the article " Analysis of the mobile medical business model and exploration of the future direction ", the author only gave a brief introduction to the action of BAT in the medical field. Since the market is always dynamic, and detailed inventory is inevitable, it is only done here. A cross section analysis.

BAT is not only the most successful companies in China during this period, but also fully qualified to be the leader of what we call mobile medical care during this period. Many of the operational decision-makers in BAT and its investment companies are now elites in the intellectual community who deal with a large number of issues related to medical services. We cannot help but feel that they must explore these issues from a strategic perspective. The common utilitarian-based discussion has hindered us from understanding the truth behind the amazing progress that is taking place in the medical field.

We have decided to choose BAT as a typical case for us to examine mobile medical care in this period. It is best to start with this: take time to look at their own business, investment layout and external cooperation in the medical field.

Baidu

Baidu want to focus on data, providing ammunition for the big data computing AI Artificial Intelligence. When the medical data accumulated large enough data on these scenarios imaginative, including disease surveillance, prevention and control of disease, clinical research, medical diagnosis decision, healthcare resource scheduling, family and other aspects of telemedicine, Baidu "brain" will get More comprehensive information including personal physiology. Baidu Medical Brain will combine Baidu's experience and technical means in the field of big data to support different levels of health decision-making from personal health management to big medical, big data research, and public health policy management.

Pre-investment is more conservative

Baidu's investment in the medical industry is relatively conservative, and most of its actions are concentrated on its own cloud health platform and cloud health hardware. In 2013, the "Baidu healthy" line, 2014, Baidu Baidu open its big data engine to start all walks of life access to information systems, the use of large data factory and Baidu brain for data processing and finishing, such as access to health information in Beijing The system; on the other hand, records people's health data, such as its Dulife smart wearables, through mobile health platforms and smart wearable devices.

In June 2013, Baidu's pre-medical inquiry platform was launched, relying on Baidu to know expert resources and case questions and answers, as well as good doctor online, 39 health network, seeking medical advice network, Q&A network, child care network, China education The data of 7 medical health websites, such as Babynet and Baby Tree, help users to understand the condition through Baidu's case database before medical treatment, to avoid blind medical treatment or delay in medical treatment. In October 2014, Baidu launched a doctor online consultation service.

In December 2013, Baidu established the smart human portable device brand dulife, which is characterized by Baidu cloud service + co-brand license. At the same time as the dulife equipment, there is also the dulife platform. By embedding Baidu SDK in smart bracelets, smart scales and other devices, and accessing Baidu cloud, the platform aggregates the data of all the smart devices owned by individuals, and provides health through analysis and processing of data. The solution involves various fields such as fitness, beauty, sleep, and diet.

Baidu cooperates with domestic hardware manufacturers, provides hardware production technology by manufacturers, Baidu provides service solutions and marketing, and stores all user health data in the cloud, through Baidu big data (the part of medical care in dulife has been transferred to big data) The intelligent collection, analysis, and processing strategies achieve the goal of collecting the “user health slow data” mentioned by Li Yanhong.

In July 2014, advocated by relevant departments of Beijing, Baidu took the lead and integrated the platform of upstream intelligent health equipment manufacturers and downstream personal health service institutions. Beijing “Xiangyun Project” key project “Beijing Health Cloud” was officially released and became a global The first intelligent health management project in the area, Baidu Health Cloud became part of the “Beijing Health Cloud” program.

Fierce action 2015

At Baidu's 2014 conference, Li Yanhong ordered the three armed forces to extend their strategy from "connecting people and information" to "connecting people and services." In 2015, Baidu's medical actions became extremely fierce. In order to better form the online and offline closed loop, first of all, it has reached a strategic cooperation with the domestic medical authority 301 hospital to jointly build a mobile Internet medical online platform. Subsequently, Baidu launched the “Baidu Doctor” App as a connection point to connect patients. And medical services; in February, Baidu strategic investment in healthcare network, extending Baidu's medical service expansion to offline. In addition, according to mobile medical big coffee Dr.2, Baidu Direct will launch "medicine direct" in April, layout "online seeking medical advice", and direct drainage to offline pharmacies.

On January 15, 2015, Baidu and 301 Hospital reached a strategic cooperation, the two sides will jointly establish an O2O service model in the medical field. Baidu can use the doctors, medical technology resources and good reputation of the 301 hospital, while the 301 hospital can use Baidu's processing power in big data and Baidu's platform entry advantage. The initial cooperation with the 301 hospital is only to build an online medical service platform, which is actually aimed at building a future network hospital.

On January 28, 2015, Baidu launched the Baidu doctor App, and fully entered the mobile medical O2O. Baidu doctor mobile terminal provides users with a closed loop of service for doctors, doctors and doctors. At present, Baidu doctor APP has realized the artificial intelligence system to complete the patient's identification calculation according to the patient's input requirements, and push the three most suitable doctors for the patient. This closed-loop service mode will accumulate a large number of users for Baidu.

Cooperation with 301 is a supplement to the service, and Baidu doctors on the line are complementary to the entrance. Baidu Doctor App will use Baidu's strength in the field of mobile application distribution to enter the mobile market.

On February 15, 2015, Baidu’s tens of millions of dollars of strategic investment in healthcare networks. The Health Care Network is a portal that provides professional medical services to the public. It has launched 300 top three hospitals (about 28% of the top three hospitals in China) and more than 50,000 doctors in registration, medical consultation and referral services. Cooperation, new business micro-consultation has also covered 500 top three hospitals. Through this strategic investment, Baidu will provide technical support for image speech recognition, technology interaction, big data and artificial intelligence for the medical care network, and jointly explore the O2O service model and innovative operation mode in the medical field. At the same time, Baidu will also use this line. Medical services on and off the line.

It is understood that Baidu will release the "medicine direct" for the drug O2O on April 12. As a subdivided product of Baidu Zhida, the operation idea of ​​“medicine direct” should be similar to Baidu Direct. (Note: Baidu Direct is the official service account of the merchant on Baidu mobile platform. Based on mobile search, @account, map, personalized recommendation, etc., the customer can directly access the merchant service anytime and anywhere.) Yao Zhida will cooperate with the pharmacy. Provide users with drug search, drug purchase services in nearby pharmacies, pharmacies provide consultation and drug delivery services, and third-party drug delivery partners will be connected to solve the problem of drug delivery. Direct drug delivery will be the new platform-type e-commerce flow portal after Tmall Medical Museum and Ali Health.

Zhang Yaqin, president of Baidu, said that Baidu has created a three-level closed loop in the medical field. First, it has completed the closed loop between people and services. Baidu's large traffic can bring patient users to the hospital. The hospital can provide a wealth of hospitals, doctor information, registration and other outpatient resources for Baidu's doctor-patient dual-selection platform, and create a closed loop with medical services. Second, complete the online and offline closed loop. The online service of Baidu's doctor-patient dual-selection platform can finally provide users with a better experience of visiting the hospital through the offline service team of the hospital, and open online and offline services. Third, the closed loop of the product itself is about to be completed, that is, the closed loop of appointment for doctors, registration, and payment.

Baidu will also be launching the "Baidu Health Assistant" in April and a health management platform similar to Apple HealthKit. Regardless of the action, Baidu’s role in intelligent health is platform integrator.

Medicine Peptides

Medicine Peptides and protein drugs are emerging. There are now 35 important therapeutics on the market, and the development of biotechnology and biopharmaceutical companies is becoming increasingly global. Biotechnology drug research focuses on the application of DNA recombinant technology to develop peptides, proteins, enzymes, hormones, vaccines, cell growth factors and monoclonal antibodies that can be used in clinical applications. According to Parexl's Pharmaceutical R&D Statistical Source Book, there are currently 723 biotech drugs under FDA review (including phase â…° to iii clinical and FDA evaluation), 700 drugs are in early stage (research and preclinical). More than 200 additional drugs are in the final stage of approval (Phase iii clinical and FDA evaluation). The basic dosage form of biotech drugs is lyophilized. Although the efficacy of conventional preparations has long been clinically proven, they need to be injected frequently for a long time due to their short half-life, which is difficult to accept from the perspective of psychological and economic burden on patients. To this end, scholars around the world mainly from two aspects to study and develop convenient and reasonable drug delivery approaches and new preparations: (1) embedment agent and sustained-release injection. â‘¡ Non-injectable dosage forms, such as respiratory inhalation, rectal administration, nasal administration, oral administration and transdermal administration, etc. Injectable preparations of sustained-release biotechnological drugs are new dosage forms with promising applications. Some of them, such as microsphere injections of luteinizing hormone releasing hormone (LHRH) analogues which can be sustained-release for 1 to 3 months, have been on the market. This paper focuses on this kind of preparations.Main types of peptides and protein drug sustained-release preparations The research and development of peptides and protein drug sustained-release preparations can be divided into two types, namely, embedment agent and microsphere injection, from the perspective of development process and dosage form. The shape of the implant is a hollow micro-fine rod, one end is closed, the other end is open, and the rod material is non-biodegradable polymer such as ptfe. The lumen was filled with a mixture of drugs and silica gel (silastic, polydimethylsiloxane). The implant is embedded under the skin, and the drug is released slowly through the opening of silica gel matrix. The American Physicians' Handbook (PDR) contains a product called Norplant? Levo-18 ethyl norethinnes, used in family planning. The preparation, each with a diameter of 2.4 mm and a length of 34 mm, is surgically implanted in the inner side of the patient's upper arm with 6 thin rods. The drug can be released in the body in zero-grade mode for up to 5 years, and then removed by surgery after release,1.1.2 Micro-osmotic pump embedding agent The United States Alza company in the 1970s developed an embedding agent shaped like a capsule, which is embedded in the skin or other parts. The body fluid can penetrate through the shell, dissolve the interlayer electrolytic layer, make the volume expansion of the interlayer pressure to the plastic inner cavity, and promote the drug solution from the opening of the fixed speed release. Many biomolecular drugs, such as insulin, heparin and nerve growth factor, have been reported as model drugs in vivo and in vitro. Implants have positive significance for the treatment of chronic patients who need long-term medication, but it has the following defects: â‘  must be surgically implanted. â‘¡ The skeleton material of the preparation is non-biodegradable polymer, which needs to be removed by surgery after release. â‘¢ The preparation has irritation and discomfort in local tissues. Evaluation methods for polypeptide protein drugs: 1. Liquid chromatography 2. Spectroscopic 3. Solvent-based versions are easy to use, but need to be kept at low temperatures (2-8 degrees Celsius).

medicine peptides high,Peptide injections,buy medicine peptides high,medicine peptides for bodybuilding,medicine peptides for hgh

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com